Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | BP1002 |
Synonyms | |
Therapy Description |
BP1002 is a liposome containing an antisense oligonucleotide targeting BCL2 mRNA, which potentially decreases cancer cell viability (Cancer Res 2021;81(13_Suppl):Abstract nr 939). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
BP1002 | BP-1002|BP 1002 | BCL2 inhibitor 27 | BP1002 is a liposome containing an antisense oligonucleotide targeting BCL2 mRNA, which potentially decreases cancer cell viability (Cancer Res 2021;81(13_Suppl):Abstract nr 939). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04072458 | Phase I | BP1002 | A Clinical Trial of BP1002 in Patients With Advanced Lymphoid Malignancies | Recruiting | USA | 0 |
NCT05190471 | Phase I | BP1002 + Decitabine BP1002 | A Clinical Trial of BP1002 in Patients With Refractory/Relapsed Acute Myeloid Leukemia (AML) | Unknown status | USA | 0 |